# breast cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 36275
- Completion tokens: 10389
- Reasoning tokens: 5475
- Total tokens: 46664
- API requests reported: 3
- Elapsed seconds: 67.289
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: xAI

---
**Overall biological interpretation**  
The prognostic transcriptomic signature from breast tumor tissue is dominated by genes driving cell-cycle progression and mitotic regulation, with a slight excess of risk-associated genes (HR > 1). Higher expression of these drivers is consistently linked to shorter overall survival, consistent with a proliferation-driven aggressive phenotype in breast cancer. The signature is minimally redundant across mitosis-spindle, chromosome-segregation and ubiquitin-conjugation modules and shows strong alignment with cell-cycle ontologies, indicating that mitotic hyperactivation is a central poor-prognosis mechanism in this cohort.

**Core biological programs**  
1. **Mitotic cell-cycle progression (risk-associated)**  
   Major supporting genes: AURKA, CDC20, KIF20A, NUSAP1, PRC1, TPX2, UBE2C, CENPO, KIF4A, ZWINT.  
   Standardized pathway: KEGG Cell cycle (hsa04110), GO Positive Regulation Of Mitotic Nuclear Division (GO:0045840).  
   The genes collectively encode core mitotic regulators (spindle assembly, chromosome alignment/segregation, mitotic exit) whose coordinated upregulation is linked to aggressive proliferation; their enrichment in the risk set and STRING connectivity to PLK1 and APC/C components strengthen the program. Evidence strength is high within the dataset (multiple independent genes, tight FDRs) but is limited by absence of external-cohort HR replication.  

2. **Ubiquitin-protein ligase activity (risk-associated)**  
   Major supporting genes: UBE2C, UBE2S, RACGAP1, ANAPC2 (STRING-linked).  
   Standardized pathway: Reactome Ubiquitin-mediated proteolysis and GO Positive Regulation Of Ubiquitin-Protein Transferase Activity (GO:1904668).  
   These E2/E3-conjugating enzymes target mitotic cyclins and securin for degradation; their risk association implies dysregulated turnover that may stabilize oncogenic complexes. Evidence is dataset-supported but pathway co-membership rather than direct causation.  

3. **Centrosome and spindle duplication (risk-associated)**  
   Major supporting genes: TPX2, NUSAP1, KIF20A, AURKA.  
   Standardized pathway: KEGG Oocyte meiosis (hsa04114) intersected with mitotic spindle assembly.  
   These factors control centrosome maturation and microtubule organization; their risk pattern points to supernumerary centrosomes driving genomic instability. Evidence is gene-set consistent within the cohort but lacks independent replication statistics.

**Key genes and interaction modules**  
- **AURKA** (risk, HR 1.19): core mitotic kinase; drives centrosome separation and spindle assembly; STRING co-membership with TPX2 and CDC20.  
- **CDC20** (risk, HR 1.19): APC/C activator; STRING links it to UBE2C and ANAPC2.  
- **UBE2C** (risk, HR 1.21): E2 ubiquitin ligase; targets mitotic substrates; STRING edges to multiple APC/C regulators.  
- **TPX2** (risk, HR 1.20): microtubule-stabilizing factor; STRING network with AURKA, NUSAP1, PRC1.  
- **NUSAP1** (risk, HR 1.19): microtubule-associated; STRING-linked to KIF4A and DLGAP5.  
- **PRC1** (risk, HR 1.19): cytokinesis regulator; STRING co-membership with AURKA and DLGAP5.  
- **KIF20A** (risk, HR 1.22): mitotic kinesin; STRING network with PLK1 and RACGAP1.  
- **CENPO** (risk, HR 1.19): kinetochore protein; STRING-linked to BUB1B and ZWINT.  
- **KIF4A** (risk, HR 1.20): chromosome passenger complex member; STRING edges to BUB1B.  
- **UHRF1** (risk, HR 1.21): epigenetic regulator of mitosis; indirect co-expression link to cell-cycle genes.

**Validation priorities**  
1. **Mechanistic hypothesis**: Functional CRISPR validation of AURKA/TPX2 in isogenic breast-cancer models to test mitotic-spindle phenotypes and OS impact. Prioritization: direct mitotic drivers with multiple STRING partners; dataset provides HR/P/FDR; external evidence mixed (some oncogene but no validated OS causality); next step—orthotopic mouse models with survival readout. Classification: Supported hypothesis.  

2. **Biomarker**: Prospective IHC panel of AURKA, CDC20, UBE2C in independent breast-cancer cohorts with OS endpoints. Prioritization: strong dataset signal plus STRING hub status; no external HR replication supplied; next step—multicenter tissue microarray with Cox modeling. Classification: Supported hypothesis.  

3. **Interaction/network hypothesis**: Orthogonal STRING/STRING-edge validation or BioID proximity labeling of top mitotic genes to confirm direct mitotic-complex partners. Prioritization: STRING evidence already present; dataset supplies co-enrichment; external evidence is co-occurrence only; next step—in vitro co-IP or proximity labeling. Classification: Exploratory hypothesis.  

4. **Confounding or composition check**: Estimate tumor-purity-adjusted HRs using ESTIMATE or CIBERSORT in the current cohort and re-test top genes. Prioritization: potential cell-composition bias in bulk RNA-seq; dataset FDRs are raw; external evidence (tumor-purity literature) argues for caution; next step—microdissected RNA-seq or single-cell OS correlation. Classification: Supported hypothesis.  

5. **Therapeutic target**: Evaluate MK-5108 (AURKA inhibitor) or similar mitotic agents in preclinical breast-cancer models stratified by mitotic-gene score. Prioritization: dataset risk genes are established mitotic targets; no drug-OS data supplied; external evidence mixed (oncogene but toxicity concerns); next step—xenograft survival studies. Classification: Exploratory hypothesis.

**Evidence grounding**  
All HR, P and FDR values are direct evidence from the supplied analysis result table. Pathway assignments rest on GO/KEGG/Reactome annotations and STRING edges (pathway co-membership). Disease-association and expression/tissue evidence derive from the breast-tumor context and prior literature records (e.g., AURKA/CDC20 mitotic roles). No external-cohort HR statistics were supplied, so independent statistical validation is absent. STRING and literature records are contextual and may overlap with dataset genes; no conflicting directions were observed. All interpretations remain exploratory given the lack of replication statistics.

**Limitations and alternative explanations**  
- Absence of independent-cohort HR replication or FDRs; external validation was not performed.  
- Potential tumor-purity or stromal-composition bias in bulk RNA-seq; can be addressed by purity-adjusted modeling or single-cell OS correlation.  
- Heterogeneity in breast-cancer subtypes/stages may drive mitotic-gene signals; stratification by PAM50 or stage would help.  
- Treatment-exposure heterogeneity (endocrine vs chemotherapy) may confound OS; matching on therapy history is advisable.  
- Association-versus-causation ambiguity; mitotic overexpression may be passenger rather than driver; functional knockdown studies are required to distinguish.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=10, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
